✦ LIBER ✦

High-performance frontal analysis for the study of protein binding of troglitazone (CS-045) in albumin solution and in human plasma

✍ Scribed by Akimasa Shibukawa; Takeshi Sawada; Chikako Nakao; Takashi Izumi; Terumichi Nakagawa

Publisher: Elsevier Science
Year: 1995
Tongue: English
Weight: 442 KB
Volume: 697
Category: Article
ISSN: 1873-3778
DOI: 10.1016/0021-9673(94)00929-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High-performance capillary electrophores

High-performance capillary electrophoresis/frontal analysis for the study of protein binding of a basic drug

✍ Akimasa Shibukawa; Yasuki Yoshimoto; Toshio Ohara; Terumichi Nakagawa 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 437 KB

Use of a human serum albumin-based stati

Use of a human serum albumin-based stationary phase for high-performance liquid chromatography as a tool for the rapid determination of drug-plasma protein binding

✍ Terence A. G. Noctor; Maria J. Diaz-Perez; Irving W. Wainer 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 256 KB 👁 1 views

A validated high-performance liquid chro

A validated high-performance liquid chromatographic method for the determination of moclobemide and its two metabolites in human plasma and application to pharmacokinetic studies

✍ Alina Plenis; Aleksandra Chmielewska; Lucyna Konieczna; Henryk Lamparczyk 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 179 KB 👁 3 views

A rapid high performance liquid chromato

A rapid high performance liquid chromatographic method for the analysis of choline in human plasma and peritoneal dialysis effluent: Application in the assessment of choline loss in continuous ambulatory peritoneal dialysis

✍ Lawrence E. Webb; Thomas M. Pavlina; J.Thomas Hjelle 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 521 KB

Development and validation of a high-per

Development and validation of a high-performance liquid chromatography–tandem mass spectrometry method for the determination of the novel inhibitor of angiogenesis E-3810 in human plasma and its application in a clinical pharmacokinetic study

✍ Federica Sala; Renzo Bagnati; Valeria Livi; Roberta Cereda; Maurizio D'Incalci; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 195 KB

E‐3810, 6‐[[7‐[(1‐aminocyclopropyl)methoxy]‐6‐methoxy‐4‐quinolyl]oxy]‐__N__‐methyl‐naphthalene‐1‐carboxamide, is a novel, potent, dual inhibitor of vascular endothelial growth factor and fibroblast growth factor receptors with antiangiogenic properties, now under early clinical evaluation as an anti

Development and validation of a high-per

Development and validation of a high-performance liquid chromatography–tandem mass spectrometry method for the determination of the novel proteasome inhibitor CEP-18770 in human plasma and its application in a clinical pharmacokinetic study

✍ Federica Sala; Elena Marangon; Renzo Bagnati; Valeria Livi; Roberta Cereda; Maur 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB

## Abstract CEP‐18770, [(1__R__)‐1‐{[(2__S__,3__R__)‐3‐hydroxy‐2‐{[(6‐phenyl‐2‐pyridinyl)carbonyl]amino}butanoyl]amino}‐3‐methylbutyl]boronic acid, is a novel proteasome inhibitor, now under early clinical evaluation as an anticancer agent. To investigate its clinical pharmacokinetics, a high‐perfo